Latest news, press releases, and SEC filings for SCYNEXIS Inc (SCYX) https://caymanjournal.com/stock/SCYX en-us Copyright 2026, Cayman Journal editorial@caymanjournal.com (Editorial Team) webmaster@caymanjournal.com (Web Master) Tue, 28 Apr 2026 01:20:02 GMT 60 https://caymanjournal.com/logo.png https://caymanjournal.com 144 144 # 📜 What This Document Is 🗳️ This document is a Preliminary Proxy Statement, which is essentially a mandatory educational guide for shareholders. It was filed by SCYNEXIS, Inc., to prepare investors for their 2026 Annual Meeting of Stockholders. 👉 The primary purpose is to tell you exactly what https://caymanjournal.com/stock/SCYX/sec-filing/0001140361-26-015668 https://caymanjournal.com/stock/SCYX/sec-filing/0001140361-26-015668 Mon, 20 Apr 2026 00:00:00 GMT SEC Filing # 🧾 What This Document Is This is an **8-K filing**, a report companies use to announce major events to investors. In this case, SCYNEXIS is announcing it has **completed the acquisition** of a new drug candidate called PXL-770 (now named SCY-770) from a French company, Poxel S.A. It’s a press rele https://caymanjournal.com/stock/SCYX/sec-filing/0001193125-26-133250 https://caymanjournal.com/stock/SCYX/sec-filing/0001193125-26-133250 Tue, 31 Mar 2026 00:00:00 GMT SEC Filing # 🧾 What This Document Is This is an 8-K filing from SCYNEXIS, a biotech company. Attached is the main event: a **Securities Purchase Agreement**. Think of it as a formal IOU and rulebook for a major cash deal. The company is selling stock and warrants to a group of investors to raise money. This d https://caymanjournal.com/stock/SCYX/sec-filing/0001193125-26-133259 https://caymanjournal.com/stock/SCYX/sec-filing/0001193125-26-133259 Tue, 31 Mar 2026 00:00:00 GMT SEC Filing